Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe.

Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several statin monotherapies and combination therapies of statin with ezetimibe (E) were examined. The statins evaluated were: atorvastatin (A) at doses of 10, 20, 40 and 80 mg; fluvastatin (F) at doses of 20, 40 and 80 mg; lovastatin (L) at doses of 10, 20 and 40 mg; pravastatin (P) at doses of 10, 20, 40 and 80 mg; rosuvastatin (R) at doses of 5, 10, 20 and 40 mg; and simvastatin (S) at doses of 10, 20, 40 and 80 mg. E was combined with A, L, P, or S.